Technology
Health
Pharmaceutical

Eagle Pharmaceuticals

$54.03
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.68 (-1.24%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell EGRX and other stocks, options, ETFs, and crypto commission-free!

About

Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. Read More The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Employees
96
Headquarters
Woodcliff Lake, New Jersey
Founded
2007
Market Cap
752.61M
Price-Earnings Ratio
21.13
Dividend Yield
0.00
Average Volume
230.66K
High Today
$54.65
Low Today
$53.36
Open Price
$54.37
Volume
118.06K
52 Week High
$85.66
52 Week Low
$36.03

Collections

Technology
Health
Pharmaceutical
Alcohol
Beverages
Food
2014 IPO
US

News

Yahoo FinanceMay 15

Eagle Pharmaceuticals, Inc. to Present at 2019 RBC Capital Markets Global Healthcare Conference

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 2019 RBC Capital Markets Global Healthcare Conference as follows: Date: Wednesday, May 22, 2019 Time: 10:00 a.m. Eastern Daylight Time Location: InterContinental New York Barclay, NYC Webcast: http://www.veracast.com/webcasts/rbc/healthcare2019/96314260749.cfm Scroll to continue with...

0
Yahoo FinanceMay 9

Hedge Funds Have Never Been More Bullish On Eagle Pharmaceuticals Inc

Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each day. However, hedge funds' consensus picks on average deliver market beating returns. For example in the first 2.5 months of this year the Standard and Poor’s 500 Index returned appr...

13
TradingNewsNowMay 9

Stock Highlights: Eagle Pharmaceuticals (NASDAQ: EGRX)

Eagle Pharmaceuticals is in the drug manufacturers industry and is in the healthcare sector. The company CEO is Scott L. Tarriff. Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Previous Intraday Trading Performance: The EGRX stock showed a previous change of 2.63% with an open at 57.07 and a close of 58.45. It reached an intraday high of 59.58 and a low of 55.40. See...

9

Earnings

$0.53
$0.76
$0.99
$1.22
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
$0.84 per share
Actual
$1.01 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.